Colorectal

Targeting Inflammation Could Help Treat Drug-Resistant Bowel Cancer

(ICR [UK]) Nov 20, 2018 - Some bowel cancers that are resistant to treatment could be re-sensitised using drugs that reduce inflammation, according to new research.

read article

Difficult-to-Treat Bowel Cancers Respond In First Study Of New Drug Combination

(ECCO) Nov 15, 2018 - Early results from a phase I trial in a small group of patients with advanced cancer using two drugs (nivolumab and pixatimod) that stimulate the immune system report that patients with bowel cancer may benefit from the combination.

read press release

Patients With Cancers Of The Gullet, Stomach And Bowel Respond Well To New Anti-HER2 Drug

(ECCO) Nov 13, 2018 - An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumour activity in a number of cancers including those of the gullet (oesophagus), stomach and bowel.

read press release

Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting

(NASDAQ) Nov 9, 2018 - Celyad today announced updated clinical results for the CYAD-01 program in solid tumors as well as translational research data presented at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting.

read article

Advances In Radiation Therapy Extend And Improve Lives Of Patients With Anal Cancer, Studies Find

(ASTRO) Nov 8, 2018 - Two recent studies find advances in radiation therapy are helping to prolong or improve the lives of people with anal cancer, including those whose cancer has advanced to stage IV.

read press release

Cancer Screening Test Vendor to Launch Epic EHR Implementation

(EHR Intelligence) Nov 6, 2018 - Exact Sciences signed a contract for an Epic EHR implementation to streamline order entry, customer care, and rev cycle management.

read article

Study in JNCCN Identifies Significant Factors for Reducing the Risk of Immunosuppression and Fever in People Being Treated with Chemotherapy

(NCCN) Oct 30, 2018 - Researchers find the timing and length of use for corticosteroids has a particularly strong impact on the likelihood of severe, life-threatening adverse events for people with cancer.

read press release

AstraZeneca Digs Deeper Into Cancer With Innate Stake

(Reuters) Oct 23, 2018 - AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company. Tuesday’s agreement is a coup for Innate - run by former AstraZeneca executive Mondher Mahjoubi - which gains rights to sell AstraZeneca’s newly approved rare blood cancer drug Lumoxiti as its first commercial product. AstraZeneca’s purchase of 6.26 million new shares in Innate at a price of 10 euros each, or double the market rate, marks a vote of confidence in the cancer immunotherapy specialist and Innate shares jumped 29 percent on the deal news.

read article

Spectrum Pharmaceuticals Receives FDA Approval of KHAPZORY™ (levoleucovorin) for injection

(Spectrum) Oct 23, 2018 - Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the U.S. Food and Drug Administration (FDA) has approved KHAPZORY (levoleucovorin) for injection, a folate analog for three indications: • Rescue after high-dose methotrexate therapy in patients with osteosarcoma. • Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination. • The treatment of patients with metastatic colorectal cancer in combination with fluorouracil.

read corporate press release

New Treatment Approach For Advanced Anal Cancer

(The Royal Marsden [UK]) Oct 22, 2018 - A new approach to treating advanced anal cancer is safer and more effective than the most widely used current treatment, according to the first ever randomised clinical trial in this group of patients.

read article

Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer

(BMS) Oct 22, 2018 - Combination showed 60% objective response rate (investigator-assessed). 82% of responses ongoing at time of data cutoff; median duration of response not yet reached.

read corporate press release

Immunotherapy May Become New First Line Treatment In Some Metastatic Colorectal Cancers

(ESMO 2018 Congress) Oct 22, 2018 - Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich.

read press release

Major Response To Immunotherapy In Early-stage Mismatch Repair Deficient Colon Cancer

(ESMO 2018 Congress) Oct 22, 2018 - Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 (1) from the first exploratory phase II trial to investigate this approach.

read press release

High-Dose Radiation Therapy Substantially Improves Survival In Patients Once Thought To Be Incurable

(ASTRO 2018) Oct 17, 2018 - In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggressive form of high-precision radiation therapy can greatly increase how long oligometastatic patients live and doubles how long they live without cancer. The findings will be presented in a news briefing and the plenary session at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO) next week.

read press release

Obesity Tied to Colon Cancer Risk in Younger Women

(New York Times) Oct 11, 2018 - The higher a woman’s body mass index, the greater her risk for early-onset colorectal cancer.

read article

RCSI Researchers Discover That High Chromosomal Instability May Predict Which Patients Will Benefit Most From Colorectal Cancer Drug

(Royal College of Surgeons in Ireland) Oct 10, 2018 - Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients will receive most benefit from a key drug used to treat colorectal cancer (Avastin).

read article

Bug That Causes Stomach Cancer Could Play a Role in Colorectal Cancer

(Duke Health) Oct 9, 2018 - H. pylori infection is associated with colorectal cancer risk, especially in African-Americans.

read press release

New Study Looks At Effectiveness Of Combination Therapy Against Refractory, Metastatic Colon Cancer

(UCCC/Colorado Cancer Blogs) Oct 9, 2018 - If colon cancer is caught in its early stages, patients typically have a good chance of living five years past diagnosis, and beyond. However, for patients with late-stage, metastatic colon cancer, the chance drops dramatically, to a five-year survival rate of only about 12 percent.

read article

Bayer to Showcase Latest Oncology Research at ESMO 2018 Congress

(Bayer) Oct 9, 2018 - Research presented includes expanded pivotal trial data set on pipeline compound larotrectinib for TRK fusion cancer across multiple tumor types in adult and pediatric patients.

read corporate press release

Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839

(Markets Insider) Oct 5, 2018 - Calithera Biosciences, Inc. today announced two new clinical trial collaborations to evaluate Pfizer’s palbociclib, also known as IBRANCE®, and the investigational dual-mechanism poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib, each in combination with Calithera’s glutaminase inhibitor CB-839.

read article
Next Page